LifePulse High Frequency Ventilator
Bunnell, Inc. · Decision date Sep 28, 2026
What did the FDA approve?
The FDA's Center for Devices and Radiological Health completed review of a premarket approval application 180-day supplement for the LifePulse High Frequency Ventilator, product code LSZ, submitted by Bunnell, Inc. The supplement is logged under P850064/S056, and its stated reason is a labeling change covering indications, instructions, shelf life or tradename; the decision recorded is approval. The action concerns the device's Indications for Use, not a new approval of the whole system.
The approved updated IFU reads that the device is indicated for treating pediatric patients, including neonates, who require temporary ventilatory support for acute respiratory failure. The statement also assigns the clinician responsibility for determining appropriate use and for considering the patient's respiratory status and general health when setting ventilator settings. The database entry does not describe the prior IFU wording, the basis for the change, or any clinical data, so the degree of change from the earlier labeling remains unspecified.
FDA approval order statement
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) 180-day supplement, which requested approval for an update to the Indications for Use (IFU). The approved updated IFU will read: The LifePulse High Frequency Ventilator is indicated for treating pediatric patients (including neonates) who require temporary ventilatory support for acute respiratory failure. It is the responsibility of the clinician to determine the appropriate use of the LifePulse High Frequency Ventilator. The user needs to consider the respiratory status and the general state of health of the patient in order to optimally set ventilator settings for the patients condition(s).
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Anesthesiology
- Decision date
- Sep 28, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P850064/S056
- Regulatory pathway
- PMA supplement
- Applicant
- Bunnell, Inc.
- Product code
- LSZ
- Decision code
- APPR
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: VENTILATOR, HIGH FREQUENCY.
- Applicant
- Bunnell, Inc.
- Product code
- LSZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P850064. Subsequent supplements may change the device or its indications.
FDA decision timeline
P850064 · Original PMA
MODEL 203 LIFE PULSE HIGH FREQUENCY VENTILATOR
P850064/S056 received
Application receipt date recorded by FDA.
P850064/S056 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P850064. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P850064
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bunnell, Inc. | PMA approval | Jun 30, 1988 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bunnell, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 436 Lawndale Dr., Salt Lake City, UT, 84115
Sources and methodology
- Original FDA record: P850064/S056
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records